Time Therapeutics, Inc. Report issue

For profit Phase 2
Founded: Kyoto Japan (2019)

Organization Overview

First Clinical Trial
2020
NCT04413344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Time Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

bromocriptine (parlodel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1